The effect of increasing α1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1833-1837

  Zhang, Xing Quan ^a   Schooley, Robert T ^a   Gerber, John G ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIGEN P24; INDINAVIR; NELFINAVIR; OROSOMUCOID; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; GAG PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; CELL LINE; CELL SURVIVAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

CELL LINE; CELL SURVIVAL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; OROSOMUCOID; VIRUS REPLICATION;

EID: 0032585948     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315123     Document Type: Article

References (19)

1. 1. Bilello JA, Bilello PA, Stellrecht K, et al. Human serum alpha-1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40:1491-7.
2. 2. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-47.
3. 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993; 6:511-3.
4. 4. Routledge PA, Barchowsky A, Bjornsson TD, Kitchell BB, Shand DG. Lidocaine plasma protein binding. Clin Pharmacol Ther 1980; 27:347-51.
5. 1-glycoprotein. J Lab Clin Med 1990; 116:871-8.
6. 6. Fischl MA, Richman DD, Flexner C, et al. Phase I/II study of the toxicity, pharmacokineties, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:28-34.
7. 7. Young B. Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998; 178:1497-501.
8. 8. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
9. 9. Johnson M, Nelson M, Peters B, et al. A comparison of BID and TID dosing of nelfinavir when given in combination with stavudine (d4T) and lamivudiue (3TC) for up to 48 weeks [abstract 1-216]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
10. 10. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effects. Pharmacotherapy 1999; 19:708-12.
11. 11. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997; 11:F95-9.
12. 12. Sadler MB, Elkine M, Hanson C, et al. The safety and pharmacokinetics of 141W94: an HTV protease inhibitor. Presented at the Fifth International Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, 1995.
13. 13. Yost RL, DeVane CL. Diurnal variation of alpha 1-acid glycoprotein concentration in normal volunteers. J Pharm Sci 1985; 74:777-9.
14. 14. Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in 80 newly infected individuals. Antiviral Ther 1999; 4(Suppl 1):85.
15. 15. Little S, Daar E, Keiser P, et al. The spectrum and frequency of reduced antiretroviral drug susceptibility in primary HIV infection in the United States. Antiviral Ther 1999; 4(Suppl 1):86.
16. 1-acid glycoprotein and plasma lidocaine binding. Clin Pharmacokinet 1984; 9(Suppl 1):27-31.
17. 17. Kageyama S, Anderson BD, Hoesterey BL, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alterations of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother 1994; 38:1107-11.
18. 1acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997; 175:1063-70.
19. 19. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984; 9(Suppl 1):10-7.